pinchar AQU\u00cd<\/a><\/strong><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"La pasada Sesi\u00f3n del 3 de Enero, primera de este a\u00f1o 2017, la present\u00f3 la Dra. Lidia Lara, R4 del S\u00ba de Neurolog\u00eda. El tema fue las terapias avanzadas en la enfermeda de Parkinson. Se trata de la segunda enfermedad degenerativa m\u00e1s frecuente, tras el Alzheimer, tiene mayor incidencia a partir de los 80 a\u00f1os […]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[715],"tags":[893],"class_list":["post-11160","post","type-post","status-publish","format-standard","hentry","category-maitines","tag-lara"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/posts\/11160","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/comments?post=11160"}],"version-history":[{"count":0,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/posts\/11160\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/media?parent=11160"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/categories?post=11160"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/tags?post=11160"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"imagen1\"](\"https:\/\/mileon.files.wordpress.com\/2017\/01\/imagen13.jpg\")
Se trata de la segunda enfermedad degenerativa m\u00e1s frecuente, tras el Alzheimer, tiene mayor incidencia a partir de los 80 a\u00f1os y se debe a la p\u00e9rdida de neuronas dopamin\u00e9rgicas de la sustancia negra. Tras describir la fisiopatolog\u00eda, formas de presentaci\u00f3n y complicaciones (motoras, no motoras y psiqui\u00e1tricas) de esta enfermedad, se centr\u00f3 en la apomorfina, la duodopa y la cirug\u00eda funcional. Se detallan las ventajas y limitaciones de cada una y sus estrategias de uso.<\/p>\n